奥沙利铂联合希罗达治疗晚期及复发性胃癌的临床研究

[目的]探讨奥沙利铂联合希罗达治疗晚期及复发性胃癌的临床疗效及副作用.[方法]选择晚期及复发性胃癌46例;d1给予奥沙利铂130 mg/m~2; d 1-14,口服希罗达化疗2000 mg/m~2,分两次服用,早、晚饭后半小时各1次.每3周为1周期,每位患者至少接受两个周期的化疗.[结果]所有患者共完成178个周期化疗,平均3.87个周期(2~6).化疗完成后,达到CR的有10例,达到PR的有.19例,达到SD的有10例,达到PD的有7例,有效率为63.04%.中位生存期为13.2月,中位缓解期8.1个月.患者的毒副反应均较轻,不良反应主要为骨髓抑制、神经毒性、消化道反应及手足综合征.[结论]采用奥沙利铂联合希罗达的联合治疗方案治疗晚期及复发性胃癌具有良好的疗效,毒副反应轻,值得临床推广.     

晚期及复发性胃癌替吉奥联合奥沙利铂治疗的临床分析

目的:分析替吉奥胶囊联合奥沙利铂治疗晚期及复发性胃癌的疗效和副作用.方法:对我院2008年6月～2010年12月27例晚期及复发性胃癌患者采用替吉奥胶囊联合奥沙利铂治疗二个周期,对疗效和副作用进行评价.结果:本组21例患者完全缓解1例;部分缓解14例;稳定6例,进展5例;总有效率(CR+PR)55.56%,临床受益率为77.78%.结论:替吉奥联合奥沙利铂化疗治疗晚期及复发性胃癌的毒副作用小,近期疗效较好,临床上的远期治疗效果值得进一步研究.     

胃癌的治疗

本文介绍胃癌的治疗。     

复发性肝癌的外科治疗

我们自1985年以来对41例复发性肝癌进行了外科治疗,效果满意,本文就复发性肝癌的早期诊断及外科治疗进行探讨。 1 临床资料 本组41例复发性肝癌,男23例,女18例,年龄32岁至70岁。其中伴肝硬化者37例,HBsAg阳性者25例,抗HCV阳性者13例。原发灶≤5cm者     

复发性口腔溃疡的综合治疗

复发性口腔溃疡又称复发性阿费他口炎,口腔黏膜病中比较常见。本病多见于青壮年,女性比男性多见。病因尚不明确,但与病毒感染,     

复发性口腔溃疡的中医中药治疗

目的观察中医中药治疗复发性口腔溃疡的疗效。方法选取2010年1月至2012年1月在我院门诊就诊的60例患复发性口腔溃疡的患者,在中医辨证论治的基础上使用相应中药,同时配合外敷药物治疗,观察本组所选患者的治疗效果。结果经相应对症治疗后,60例患者中有34例治愈,12例显效,8例有效,6例无效,其中治愈率为56.67%,总有效率为90%。在服药过程中均未见患者有明显的副作用。结论中医中药经辨证治疗复发性口腔溃疡有良好的疗效,其副作用少,值得在临床上对于复发性口腔溃疡推广使用。     

复发性口腔溃疡的治疗探讨

目的对复发性口腔溃疡目前在临床上使用的治疗方法的疗效进行对比。方法随机选取我院于2010年3月——2012年7月期间收治的复发性口腔溃疡患者60例,并对这些病人的相关临床资料进行回顾性分析。结果实验组患者在经过治疗后其疗效要明显高于对照组（P〈0.05）;在经过治疗之后实验组病人在外周血T淋巴细胞亚群值以及血液流变学检测结果方面都要明显优于对照组（P〈0.05）。结论对复发性口腔溃疡采用中西医共同治疗,临床疗效显著,而且具有不良反应少以及稳定性等特点,具有临床推广价值。     

残胃癌和残胃再发癌根治性切除17例报告

目的：探讨残胃癌和残胃再发癌的手术处理方法。方法：对近10年间行根治性切除17例残胃癌和残胃再发癌的资料进行回顾性分析。结果：残胃癌病例中行残胃切除联合脾切除6例,联合胰体尾脾切除3例,联合横结肠部分切除1例,联合脾切除-横结肠部分切除1例,同时行切口疝无张力修补术1例,残胃再发癌行全残胃联合空肠切除3例。结论：行全残胃切除联合周边脏器整块切除能提高残胃癌和残胃再发癌的根治性。     

胃癌复发患者家庭照顾者死亡焦虑现状及影响因素分析

目的 了解胃癌复发患者家庭照顾者死亡焦虑现状并分析其影响因素。方法 便利抽取205例胃癌复发患者及其家庭照顾者,使用死亡焦虑量表（T - DAS）,并结合一般资料问卷、自我调节疲劳量表（SRF - S）、照顾者积极感受量表（PAC）对其进行调查。结果 胃癌复发患者家庭照顾者死亡焦虑得分为（37.94±6.92）分。回归分析结果显示,患者的日常生活能力指数,照顾者的健康自评、年龄、自我调节疲劳和积极感受影响照顾者死亡焦虑,可解释总体变异度的63.7%。结论 胃癌复发患者家庭照顾者死亡焦虑呈较高水平,患者的日常生活能力指数,照顾者的健康自评、年龄、自我调节疲劳和积极感受是其影响因素。医护人员应针对以上因素制定有效的护理措施,减轻照顾者死亡焦虑。     

伊立替康联合卡培他滨治疗晚期胃癌的临床观察

目的 评价伊立替康联合卡培他滨在晚期胃癌治疗中的有效性和安全性.方法 34例晚期胃癌患者,给予伊立替康100 mg/m2静脉注射（第1、8天）;卡培他滨1000 mg/m2,每日2次,口服（第1～14天）,每21天为一个周期,3个周期后评价疗效.结果 34例患者中1例因经济原因,只化疗1个周期,另外1例出现消化道出血,化疗1.5个周期.无完全缓解病例,部分缓解（PR）占53.1%（17/32）,稳定（SD）占18.8%（6/32）,进展（PD）占28.1%（9/32）,中位疾病进展时间为6个月,中位生存时间为10个月.不良反应主要有腹泻、恶心、呕吐、骨髓抑制,多为Ⅰ、Ⅱ度.结论 伊立替康联合卡培他滨对晚期胃癌有效,不良反应可以耐受.     

Hystopathology of gastric cancer

This study draws a random sample (334 individuals) of all patients diagnosed with stomach cancer from 1980 to 1995 at the National Cancer Institute in Rio de Janeiro, Brazil, and reviews histopathological data. Agreement between previous and present classification of the histopathological material (Laurén's classification) was considered quite substantial (kappa = 0.65). Based on this classification, a statistically nonsignificant trend towards decline in the intestinal type of stomach cancer among older individuals (60 years old or older) from both genders was observed (males: 41.0% in 1980-1985, 37.9% in 1986-1990, and 28.8% in 1991-1995; females: 41.4%, 31.5%, and 15.2%, respectively). Proportions of the intestinal type among younger patients from both genders remained stable throughout the period.     

Surgery for recurrent ovarian cancer

Cytoreductive surgery is accepted as a major treatment of primary ovarian cancer. The role in recurrent ovarian cancer remains a field of discussion and controversy, mainly owing to missing data from prospective randomized trials and lack of universal definitions. Retrospective data indicate that complete resection of recurrent tumor formations should be aimed for, since survival prolongation is mainly seen for patients with no residual disease. Thus, it is most important to find predictors of complete resection, on the one hand to offer the best therapeutic chances to patients, but on the other hand to protect patients with limited life expectancy from additional surgical burden. The first prospective surgical trial in recurrent ovarian cancer, AGO-DESKTOP II validated a score ('AGO score') for complete resection. It was shown that patients with a good general condition (ECOG 0), no residual disease after surgery for primary ovarian cancer and absence of ascites in presurgical diagnostics have a 76% likelihood of undergoing complete resection. In this article, further recent data regarding surgery for recurrent ovarian cancer are going to be discussed and the advantages of incorporating these patients into randomized trials are highlighted.     

Therapy for recurrent ovarian cancer

Primary treatment of advanced ovarian cancer is well established. The combination of tumor debulking and platinum/taxane polychemotherapy has led to improved treatment results in recent years. However, most patients with ovarian cancer will relapse, rendering treatment of recurrent ovarian cancer of great clinical interest. Relapse therapy should depend on the treatment-free interval. Patients with progressive disease during primary treatment or cancer relapse within 6 months after the completion of primary treatment are platinum refractory, and, therefore, prognostically unfavorable. For these patients with poor outcome, quality of life should be predominantly considered before initiation of treatment. Cancer relapse after an interval of more than 6 months after the completion of primary treatment cannot be cured; however, platinum-based chemotherapy, in individual cases combined with secondary tumor debulking, can lead to persisting remissions.